{"id":786501,"date":"2023-09-27T13:19:44","date_gmt":"2023-09-27T17:19:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/"},"modified":"2023-09-27T13:19:44","modified_gmt":"2023-09-27T17:19:44","slug":"crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","title":{"rendered":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ZUG, Switzerland and BOSTON, Sept.  27, 2023  (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38<sup>th<\/sup> Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023.<\/p>\n<p align=\"left\">\n        <strong>Title: <\/strong>Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CAR T cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency <br \/><strong>Abstract Number: <\/strong>274 <br \/><strong>Location: <\/strong>Exhibit Halls A and B1<br \/><strong>Date and Time:\u00a0<\/strong>Saturday, November 4, 2023, 9:00 a.m. \u2013 8:30 p.m.<\/p>\n<p align=\"left\">\n        <strong>Title: <\/strong>Allogeneic CAR T cells targeting Liv-1 for Breast Cancer <br \/><strong>Abstract Number:<\/strong> 324 <br \/><strong>Location: <\/strong>Exhibit Halls A and B1<br \/><strong>Date and Time:\u00a0<\/strong>Saturday, November 4, 2023, 9:00 a.m. \u2013 8:30 p.m.<\/p>\n<p align=\"left\">\n        <strong>Title: <\/strong>Development of allogeneic, potency-edited, anti-GPC3 CAR-T cells for the treatment of hepatocellular carcinoma <br \/><strong>Abstract Number: <\/strong>264<br \/><strong>Location: <\/strong>Exhibit Halls A and B1<br \/><strong>Date and Time:\u00a0<\/strong>Saturday, November 4, 2023, 9:00 a.m. \u2013 8:30 p.m.<\/p>\n<p align=\"justify\">\n        <strong>About CRISPR Therapeutics<br \/><\/strong>CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR\/Cas9 platform. CRISPR\/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&amp;D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zvl4vuMbfgRW_r7pOe94J7uwEeeF5NIj0UgobKDaUWYyTUW3P3MGW78arWGEgTCF3KJimwk7b3Qu1RFiibI3ug==\" rel=\"nofollow noopener\" target=\"_blank\">www.crisprtx.com<\/a>.<\/p>\n<p align=\"justify\">CRISPR THERAPEUTICS<sup>\u00ae<\/sup> word mark and design logo and CTX112\u2122 are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Susan Kim<br \/>+1-617-315-4600<br \/>susan.kim@crisprtx.com<\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Rachel Eides<br \/>+1-617-315-4493<br \/>rachel.eides@crisprtx.com<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTUxMzJhY2YtMzkyMy00ODE4LTk0ZjQtN2YzNDk0MDg3ZmJhLTEwNjE0ODI=\/tiny\/CRISPR-Therapeutics-AG.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023. Title: Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CAR T cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency Abstract Number: 274 Location: Exhibit Halls A and B1Date and Time:\u00a0Saturday, November 4, 2023, 9:00 a.m. \u2013 8:30 p.m. Title: Allogeneic CAR T cells targeting Liv-1 for Breast Cancer Abstract Number: 324 Location: Exhibit Halls &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-786501","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023. Title: Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CAR T cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency Abstract Number: 274 Location: Exhibit Halls A and B1Date and Time:\u00a0Saturday, November 4, 2023, 9:00 a.m. \u2013 8:30 p.m. Title: Allogeneic CAR T cells targeting Liv-1 for Breast Cancer Abstract Number: 324 Location: Exhibit Halls &hellip; Continue reading &quot;CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-27T17:19:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting\",\"datePublished\":\"2023-09-27T17:19:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\"},\"wordCount\":357,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\",\"name\":\"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=\",\"datePublished\":\"2023-09-27T17:19:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk","og_description":"ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) &#8212; CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced poster presentations of preclinical data at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, CA or virtually from November 1 to 5, 2023. Title: Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CAR T cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency Abstract Number: 274 Location: Exhibit Halls A and B1Date and Time:\u00a0Saturday, November 4, 2023, 9:00 a.m. \u2013 8:30 p.m. Title: Allogeneic CAR T cells targeting Liv-1 for Breast Cancer Abstract Number: 324 Location: Exhibit Halls &hellip; Continue reading \"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-27T17:19:44+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting","datePublished":"2023-09-27T17:19:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/"},"wordCount":357,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","name":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=","datePublished":"2023-09-27T17:19:44+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyOTE1OSM1ODMzODU1IzIwNDk5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crispr-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=786501"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786501\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=786501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=786501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=786501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}